Publication Name	World Journal of Hepatology
Manuscript ID	107671
Country	Taiwan

Received	2025-03-28 05:57
Peer-Review Started	2025-03-28 06:41
To Make the First Decision
Return for Revision	2025-05-12 08:26
Revised	2025-05-23 00:06
Second Decision	2025-08-01 02:40
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2025-08-01 11:21
Articles in Press	2025-08-01 11:21
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2025-09-17 06:32
Publish the Manuscript Online	2025-09-25 11:24

ISSN	1948-5182 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Minireviews
Article Title	Targeting glypican-3 as a new frontier in liver cancer therapy
Manuscript Source	Invited Manuscript
All Author List	Chen-Shiou Wu, Teng-Yu Lee and Hsu-Wen Chao
Funding Agency and Grant Number
Corresponding Author	Hsu-Wen Chao, Associate Professor, PhD, Department of Physiology, School of Medicine, Taipei Medical University, Wuxing St, Xinyi District, Taipei 110301, Taiwan. chaohw3619@tmu.edu.tw
Key Words	Glypican-3; Hepatocellular carcinoma; Chimeric antigen receptor T-cell; Wnt; Immunotherapy
Core Tip	This review provides a comprehensive overview of glypican-3 (GPC3)-targeted strategies in hepatocellular carcinoma (HCC), including monoclonal and bispecific antibodies, chimeric antigen receptor-T cell therapies, vaccines, and photodynamic approaches. It further explores GPC3’s role in molecular imaging, radiomics, and liquid biopsy. Despite challenges in clinical translation, ongoing trials and novel combination therapies highlight the potential of GPC3-based approaches to improve treatment specificity, overcome resistance, and guide personalized therapy in HCC.
Publish Date	2025-09-25 11:24
Citation	<p>Wu CS, Lee TY, Chao HW. Targeting glypican-3 as a new frontier in liver cancer therapy. <i>World J Hepatol</i> 2025; 17(9): 107671</p>
URL	https://www.wjgnet.com/1948-5182/full/v17/i9/107671.htm
DOI	https://dx.doi.org/10.4254/wjh.v17.i9.107671

Full Article (PDF)	WJH-17-107671-with-cover.pdf
Manuscript File	107671_Auto_Edited_014744.docx
Answering Reviewers	107671-answering-reviewers.pdf
Audio Core Tip	107671-audio.m4a
Conflict-of-Interest Disclosure Form	107671-conflict-of-interest-statement.pdf
Copyright License Agreement	107671-copyright-assignment.pdf
Non-Native Speakers of English Editing Certificate	107671-non-native-speakers.pdf
Peer-review Report	107671-peer-reviews.pdf
Scientific Misconduct Check	107671-scientific-misconduct-check.png
Scientific Editor Work List	107671-scientific-editor-work-list.pdf
CrossCheck Report	107671-crosscheck-report.pdf